Do I need a prescription for Safinamide 100mg tablets?

Safinamide 100mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Safinamide 100mg tablets?

Safinamide 100mg tablets is the generic name. It is available under brand names including: Safinamide 100mg tablets, Safinamide 100mg tablets, Xadago 100mg tablets, Xadago 100mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Safinamide 100mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

100mg

Oral

Safinamide is for the treatment of parkinson's disease.

Active ingredients:

Safinamide

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.09.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N04BD03

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Safinamide

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Safinamide

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Safinamide

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Safinamide

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

4 branded products available

4 productsShow details

4 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Safinamide on the MHRA register

Xadago 100mg tablets

Zambon UK Ltd

Xadago 100mg tablets

Pilsco Ltd

Safinamide 100mg tablets

MSN Laboratories Europe Ltd

Safinamide 100mg tablets

Alliance Healthcare (Distribution) Ltd

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£69.00indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

75 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Safinamide 50mg tablets

Tablet

50mg

Same therapeutic group

Rasagiline 2mg/5ml oral solution

Oral solution

2mg/5ml

Same therapeutic group

Rasagiline 2mg/5ml oral suspension

Oral suspension

2mg/5ml

Same therapeutic group

Selegiline 19mg/5ml oral solution

Oral solution

19mg/5ml

Same therapeutic group

Selegiline 5mg/5ml oral solution

Oral solution

5mg/5ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Safinamide

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Safinamide

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

32696411000001101

dm+d ID

32696411000001101

VTM (Virtual Therapeutic Moiety)

777482000

VMP (Virtual Medicinal Product)

32696411000001101

BNF code

04090100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N04BD03

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

141 found

Half-life

22 h

Mechanism

Safinamide is a unique molecule with multiple mechanisms of action and a very high therapeutic index.

Food interactions

5 warnings

Human targets

1 target

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

2 to 4 h

Rapid with peak plasma concentrations ranging from 2 to 4 h, total bioavailability is 95%.…

Half-life

22 h

22 h

Protein binding

88–90%

Volume of distribution

1.8 litres/kg

Metabolism

The principal step is mediated by amidases which have not been identified, and produces safinamide acid.…

Elimination

76%

76% renal, 1.5% faeces

Clearance

2.71 ml

total oral clearance of plasma , which accounts for parent safinamide as well as metabolites, was on average only 17.53 ± 2.71 ml/h × kg

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.

Properties:

solid

Avg. mass: 302.35 Da

DrugBank indication

Safinamide is indicated as an add-on treatment to levodopa with or without other medicines for Parkinson’s disease

Also known as(79)

Safinamida

Safinamide

1.4.3.21

1.4.3.4

MAO-B

Monoamine oxidase type B

1.4.3.21

1.4.3.4

Dosage forms(8)

Tablet, film coated (Oral) — 65.88 MG

Tablet (Oral) — 100 mg

Tablet (Oral) — 50 mg

Tablet, film coated (Oral) — 100 mg/1

Tablet, film coated (Oral) — 50 mg/1

Tablet, coated (Oral) — 100 mg

Tablet, film coated (Oral) — 100 MG

Tablet, film coated (Oral) — 50 MG

Molecular properties(19)

Drug interactions(1487)

Known interactions with other medications. Always consult a healthcare professional.

Cilostazol

Unknown severity

DB01166

The serum concentration of Cilostazol can be increased when it is combined with Safinamide.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Safinamide.

Check this interaction

Dronabinol

Moderate

DB00470

Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Safinamide.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Safinamide.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Safinamide.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Safinamide can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Safinamide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Safinamide may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Safinamide.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Safinamide.

Check this interaction

Orphenadrine

Moderate

DB01173

Safinamide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Safinamide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Safinamide.

Check this interaction

Pramipexole

Moderate

DB00413

Safinamide may increase the sedative activities of Pramipexole.

Check this interaction

Rotigotine

Moderate

DB05271

Safinamide may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Safinamide.

Check this interaction

Sodium oxybate

Moderate

DB09072

Safinamide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Check this interaction

Suvorexant

Moderate

DB09034

Safinamide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Thalidomide

Moderate

DB01041

Safinamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Safinamide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Desmopressin

Unknown severity

DB00035

The risk or severity of hypertension can be increased when Desmopressin is combined with Safinamide.

Check this interaction

Icosapent

Unknown severity

DB00159

The risk or severity of hypertension can be increased when Icosapent is combined with Safinamide.

Check this interaction

Mesalazine

Unknown severity

DB00244

The risk or severity of hypertension can be increased when Mesalazine is combined with Safinamide.

Check this interaction

Tolmetin

Unknown severity

DB00500

The risk or severity of hypertension can be increased when Tolmetin is combined with Safinamide.

Check this interaction

Fenoprofen

Unknown severity

DB00573

The risk or severity of hypertension can be increased when Fenoprofen is combined with Safinamide.

Check this interaction

Sulindac

Unknown severity

DB00605

The risk or severity of hypertension can be increased when Sulindac is combined with Safinamide.

Check this interaction

Carprofen

Unknown severity

DB00821

The risk or severity of hypertension can be increased when Carprofen is combined with Safinamide.

Check this interaction

Phenmetrazine

Unknown severity

DB00830

The risk or severity of hypertension can be increased when Phenmetrazine is combined with Safinamide.

Check this interaction

Diflunisal

Unknown severity

DB00861

The risk or severity of hypertension can be increased when Diflunisal is combined with Safinamide.

Check this interaction

Meclofenamic acid

Unknown severity

DB00939

The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Safinamide.

Check this interaction

Oxaprozin

Unknown severity

DB00991

The risk or severity of hypertension can be increased when Oxaprozin is combined with Safinamide.

Check this interaction

Balsalazide

Unknown severity

DB01014

The risk or severity of hypertension can be increased when Balsalazide is combined with Safinamide.

Check this interaction

Ephedrine

Unknown severity

DB01364

The risk or severity of hypertension can be increased when Ephedrine is combined with Safinamide.

Check this interaction

Magnesium salicylate

Unknown severity

DB01397

The risk or severity of hypertension can be increased when Magnesium salicylate is combined with Safinamide.

Check this interaction

Salsalate

Unknown severity

DB01399

The risk or severity of hypertension can be increased when Salsalate is combined with Safinamide.

Check this interaction

Choline magnesium trisalicylate

Unknown severity

DB01401

The risk or severity of hypertension can be increased when Choline magnesium trisalicylate is combined with Safinamide.

Check this interaction

Antrafenine

Unknown severity

DB01419

The risk or severity of hypertension can be increased when Antrafenine is combined with Safinamide.

Check this interaction

Tiaprofenic acid

Unknown severity

DB01600

The risk or severity of hypertension can be increased when Tiaprofenic acid is combined with Safinamide.

Check this interaction

Epicaptopril

Unknown severity

DB02032

The risk or severity of hypertension can be increased when Epicaptopril is combined with Safinamide.

Check this interaction

Taxifolin

Unknown severity

DB02224

The risk or severity of hypertension can be increased when Taxifolin is combined with Safinamide.

Check this interaction

Oxyphenbutazone

Unknown severity

DB03585

The risk or severity of hypertension can be increased when Oxyphenbutazone is combined with Safinamide.

Check this interaction

1-benzylimidazole

Unknown severity

DB04581

The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Safinamide.

Check this interaction

Benoxaprofen

Unknown severity

DB04812

The risk or severity of hypertension can be increased when Benoxaprofen is combined with Safinamide.

Check this interaction

Cimicoxib

Unknown severity

DB05095

The risk or severity of hypertension can be increased when Cimicoxib is combined with Safinamide.

Check this interaction

Amibegron

Unknown severity

DB05395

The risk or severity of hypertension can be increased when Amibegron is combined with Safinamide.

Check this interaction

Solabegron

Unknown severity

DB06190

The risk or severity of hypertension can be increased when Solabegron is combined with Safinamide.

Check this interaction

Saralasin

Unknown severity

DB06763

The risk or severity of hypertension can be increased when Safinamide is combined with Saralasin.

Check this interaction

Azapropazone

Unknown severity

DB07402

The risk or severity of hypertension can be increased when Safinamide is combined with Azapropazone.

Check this interaction

Salicylamide

Unknown severity

DB08797

The risk or severity of hypertension can be increased when Safinamide is combined with Salicylamide.

Check this interaction

Tyramine

Unknown severity

DB08841

The risk or severity of hypertension can be increased when Safinamide is combined with Tyramine.

Check this interaction

Showing 50 of 1487 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid excessive or chronic alcohol consumption. Ingesting alcohol may increase the sedative effects of safinamide.

Advice

Avoid St. John's Wort. This herb may increase the risk of serotonin syndrome, and therefore, concomitant use is contraindicated.

Avoid Alcohol

Avoid tyramine-containing foods and supplements. Avoid foods containing high amounts of tyramine (>150mg) as these foods may cause a significant elevation in blood pressure. Tyramine-containing foods include cheese, red wine, fava beans, pickled food, cured food, and alcoholic beverages.

Advice

Take at the same time every day.

Advice

Take with or without food.

Toxicity & overdose

uncontrolled involuntary movement, falls, nausea, and trouble sleeping or falling asleep (insomnia)
Patients who have an overdose may experience hypertension (high blood pressure), orthostatic hypotension, hallucinations, psychomotor agitation, nausea, vomiting, and dyskinesia.

How it works

Mechanism of action

Safinamide is a unique molecule with multiple mechanisms of action and a very high therapeutic index. It combines potent, selective, and reversible inhibition of MAO-B with blockade of voltage-dependent Na+ and Ca2+ channels and inhibition of glutamate release. Safinamide has neuroprotective and neurorescuing effects in MPTP-treated mice, in the rat kainic acid, and in the gerbil ischemia model.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Rapid with peak plasma concentrations ranging from 2 to 4 h, total bioavailability is 95%. Food prolonged the rate and did not affect the extent of absorption of safinamide.

Half-life

22 h

Protein binding

88–90%

Volume of distribution

1.8 litres/kg

Metabolism

The principal step is mediated by amidases which have not been identified, and produces safinamide acid. It is also metabolized to O-debenzylated safinamide and N-delkylated amine. The N-dealkylated amine is then oxidized to a carboxylic acid and finally glucuronidated.

Dealkylation reactions are mediated by cytochrome P450s (CYPs), especially CYP3A4. Safinamide acid binds to organic anion transporter 3 (OAT3), but no clinical relevance of this interaction has been determined. Safinamide also binds to ABCG2 transiently.

No other transporter affinities have been found in preliminary studies.

Route of elimination

76% renal, 1.5% faeces

Clearance

total oral clearance of plasma , which accounts for parent safinamide as well as metabolites, was on average only 17.53 ± 2.71 ml/h × kg

Drug targets(1)

Proteins and enzymes this drug interacts with in the body

Amine oxidase [flavin-containing] B

BE0002196

MAOB

antagonist

Specific functionelectron transfer activity

Cellular location

Mitochondrion outer membrane

General function & pharmacology

Catalyzes the oxidative deamination of primary and some secondary amines such as neurotransmitters, and exogenous amines including the tertiary amine, neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), with concomitant reduction of oxygen to hydrogen peroxide and participates in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues .
PMID:11049757 PMID:11134050 PMID:20493079 PMID:8316221 PMID:8665924

Preferentially degrades benzylamine and phenylethylamine PMID:11049757 PMID:11134050 PMID:20493079 PMID:8316221 PMID:8665924

Metabolizing enzymes(7)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

MAOAAmine oxidase [flavin-containing] A

inhibitor

CYP3A4Cytochrome P450 3A4

substrate

CYP1A1Cytochrome P450 1A1

inhibitor

CYP1A2Cytochrome P450 1A2

inhibitor

CYP2D6Cytochrome P450 2D6

inhibitor

CYP2C19Cytochrome P450 2C19

inhibitor

CYP3A5Cytochrome P450 3A5

inhibitor

Transporters(2)

Proteins that transport this drug across cell membranes

Broad substrate specificity ATP-binding cassette transporter ABCG2

BE0001067

ABCG2

inhibitor

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Broad substrate specificity ATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes a wide variety of physiological compounds, dietary toxins and xenobiotics from cells .
PMID:11306452 PMID:12958161 PMID:19506252 PMID:20705604 PMID:28554189 PMID:30405239 PMID:31003562

Involved in porphyrin homeostasis, mediating the export of protoporphyrin IX (PPIX) from both mitochondria to cytosol and cytosol to extracellular space, it also functions in the cellular export of heme .
PMID:20705604 PMID:23189181
Also mediates the efflux of sphingosine-1-P from cells .
PMID:20110355
Acts as a urate exporter functioning in both renal and extrarenal urate excretion .
PMID:19506252 PMID:20368174 PMID:22132962 PMID:31003562 PMID:36749388

In kidney, it also functions as a physiological exporter of the uremic toxin indoxyl sulfate (By similarity). Also involved in the excretion of steroids like estrone 3-sulfate/E1S, 3beta-sulfooxy-androst-5-en-17-one/DHEAS, and other sulfate conjugates .
PMID:12682043 PMID:28554189 PMID:30405239

Mediates the secretion of the riboflavin and biotin vitamins into milk (By similarity). Extrudes pheophorbide a, a phototoxic porphyrin catabolite of chlorophyll, reducing its bioavailability (By similarity).

Plays an important role in the exclusion of xenobiotics from the brain (Probable). It confers to cells a resistance to multiple drugs and other xenobiotics including mitoxantrone, pheophorbide, camptothecin, methotrexate, azidothymidine, and the anthracyclines daunorubicin and doxorubicin, through the control of their efflux .
PMID:11306452 PMID:12477054 PMID:15670731 PMID:18056989 PMID:31254042

In placenta, it limits the penetration of drugs from the maternal plasma into the fetus (By similarity). May play a role in early stem cell self-renewal by blocking differentiation (By similarity).

In inflammatory macrophages, exports itaconate from the cytosol to the extracellular compartment and limits the activation of TFEB-dependent lysosome biogenesis involved in antibacterial innate immune response

Solute carrier organic anion transporter family member 3A1

BE0003661

SLCO3A1

substrate

Specific functionorganic anion transmembrane transporter activity

Cellular location

Basolateral cell membrane

General function & pharmacology

Putative organic anion antiporter with apparent broad substrate specificity. Recognizes various substrates including thyroid hormone L-thyroxine, prostanoids such as prostaglandin E1 and E2, bile acids such as taurocholate, glycolate and glycochenodeoxycholate and peptide hormones such as L-arginine vasopressin, likely operating in a tissue-specific manner .
PMID:10873595 PMID:14631946 PMID:16971491 PMID:19129463 PMID:30063921

The transport mechanism, its electrogenicity and potential tissue-specific counterions remain to be elucidated (Probable)

Scientific references(5)

Onofrj M., Bonanni L., Thomas A.

An expert opinion on safinamide in Parkinson's disease.

Expert Opinion Investig Drugs

2008 Jul17(7):1115-25. doi: 10.1517/13543784.17.7.1115

PMID: 18549347 DOI: 10.1517/13543784.17.7.1115

Stocchi F., Vacca L., Grassini P., De Pandis M.F., Battaglia G., Cattaneo C., Fariello R.G.

Symptom relief in Parkinson disease by safinamide.

Neurology

200667(7_suppl_2). doi: 10.1212/wnl.67.7_suppl_2.s24

PMID: 17030737 DOI: 10.1212/wnl.67.7_suppl_2.s24

Marzo A., Dal Bo L., Monti N.C., Crivelli F., Ismaili S., Caccia C., Cattaneo C., Fariello R.G.

Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.

Pharmacological Research

200450(1):77-85. doi: 10.1016/j.phrs.2003.12.004

PMID: 15082032 DOI: 10.1016/j.phrs.2003.12.004

Leuratti C., Sardina M., Ventura P., Assandri A., Muller M., Brunner M.

Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers.

Pharmacology

201392(3-4):207-16. doi: 10.1159/000354805. Epub 2013 Oct 11

PMID: 24136086 DOI: 10.1159/000354805

Schapira A.H.

Safinamide in the treatment of Parkinson's disease.

Expert Opinion on Pharmacotherapy

2010 Sep11(13):2261-8. doi: 10.1517/14656566.2010.511612

PMID: 20707760 DOI: 10.1517/14656566.2010.511612

ATC classification(1 code)

ATC N04BD03

Affected organisms(1)

Humans and other mammals

Salt forms(1)

Safinamide mesylate(DBSALT002034)

Commercial products(16)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Safinamide

DB06654

CAS number

133865-89-1

UNII (FDA)

90ENL74SIG

InChI Key (molecular fingerprint)

NEMGRZFTLSKBAP-LBPRGKRZSA-N

Additional database identifiers

Drugs Product Database (DPD)

23038

ChEBI

134718

PubChem Compound

131682

PubChem Substance

347827780

ChemSpider

116349

BindingDB

50078694

Wikipedia

Safinamide

ChEMBL

CHEMBL396778

ZINC

ZINC000053084692

RxCUI

1922448

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6834

GenAtlas

MAOB

GeneCards

MAOB

GenBank Gene Database

S62734

GenBank Protein Database

398415

Guide to Pharmacology

2490

UniProtKB

P27338

UniProt Accession

AOFB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6833

GenAtlas

MAOA

GeneCards

MAOA

GenBank Gene Database

M68840

GenBank Protein Database

187353

Guide to Pharmacology

2489

UniProtKB

P21397

UniProt Accession

AOFA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2595

GeneCards

CYP1A1

GenBank Gene Database

K03191

GenBank Protein Database

181276

Guide to Pharmacology

1318

UniProtKB

P04798

UniProt Accession

CP1A1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2638

GenAtlas

CYP3A5

GeneCards

CYP3A5

GenBank Gene Database

J04813

GenBank Protein Database

181346

Guide to Pharmacology

1338

UniProtKB

P20815

UniProt Accession

CP3A5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:74

GenAtlas

ABCG2

GeneCards

ABCG2

GenBank Gene Database

AF103796

GenBank Protein Database

4185796

Guide to Pharmacology

792

UniProtKB

Q9UNQ0

UniProt Accession

ABCG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10952

GeneCards

SLCO3A1

GenBank Gene Database

AB031050

GenBank Protein Database

6683741

UniProtKB

Q9UIG8

UniProt Accession

SO3A1_HUMAN

Patent information

3 active patents

8076515

United States

Approved 13 Dec 2011 · Expires 10 Dec 2028

2y 8m

8283380

United States

Approved 9 Oct 2012 · Expires 1 Sept 2027

1y 5m

8278485

United States

Approved 2 Oct 2012 · Expires 8 Jun 2027

1y 2m

The earliest active patent expires June 2027. Generic versions may become available after this date.

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Safinamide 100mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
10

Chemical identifiers

Safinamide

Additional database identifiers

Patent information

DrugBank citations

Safinamide 100mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science10

Chemical identifiers

Safinamide

Additional database identifiers

Patent information

DrugBank citations

Deep science
10